Downstream Issues Still Beset Production
To Protect the Bottom Line, Biomanufacturers Invest in Downstream Purification Technology
GEN Roundup: No Detail Is Too Small in Bioprocess Scaleup
A Change in Scale Can Change Everything
Amid Election Clamor, Research Issues Surface
Sounds of Science Podcast
10 Takeover Targets of 2016
Which Biopharmas Do Wall Street Watchers View As Top Buyout Candidates?
Geron’s hESC Assets
Geron, a pioneer in stem cell research founded in 1990, announced on November 14 that it was halting its stem cell therapeutic programs and is seeking partners for these assets. Full story here. Geron had been developing differentiated human embryonic stem cells (hESCs), with its lead product in Phase I for spinal cord injury. While BioTime could be a potential buyer, the firm is currently focused on research tools. Advanced Cell Technology (ACT) remains the only company left with ongoing clinical trials involving hESCs. But ACT doesn’t have a lot of cash, and the fact is that Geron had the most money. Given Geron’s financial strengths and longstanding scientific expertise, do you think another organization has what it takes to succeed where Geron failed?